Clinical trials: Histological Response
Lymphoma, B-Cell, Neurotoxicity
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
The treatment of large-cell B-cell lymphomas refractory to more than 2 lines of therapy has recently been revolutionized by the use of immunotherapies consisting of autologous genetically modified cells or CAR-T CELLS (chimeric…
- Trial name
- MR-ICANS (NCT05510596)
- Testing
- Magnetic Resonance Imaging with contrast injection, Blood withdrawal, Neuropsychological tests
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
- Conditions
- Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Adult Soft Tissue Sarcoma, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00896961
- Testing
- EF5, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer
This study investigates the role of circulating and urinary exosomal microRNAs (miRNAs) as potential biomarkers for predicting response to systemic therapy in patients with advanced renal cell carcinoma.
- Trial name
- EXO-RENAL2 (NCT07436416)
- Testing
- Circulating and Urinary Exosomal miRNA Analysis
- Where
- Slovenia
- Volunteers
- 91 people
- Sponsor
- Institute of Oncology Ljubljana
Melanoma
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors…
- Trial name
- NCT04567706
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Myelodysplastic Syndromes
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion…
- Trial name
- NCT00179621
- Testing
- Lenalidomide 5 mg, Lenalidomide 10 mg
- Where
- 38 sites in Belgium, France and 7 more
- Volunteers
- 205 people
- Sponsor
- Celgene Corporation
Neuroblastoma
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00499616
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 189 sites in United States, Australia and 4 more
- Volunteers
- 464 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Organoid
Drug Response Testing and Repurposing Using Glioblastoma Organoid
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including…
- Trial name
- NCT06782984
- Testing
- Organoid-based drug sensitivity test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Chungnam National University Hospital
Multiple Myeloma
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation
Hematopoietic reconstitution defined by a neutrophils number > 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number > 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without…
- Trial name
- Expansion (NCT00461955)
- Testing
- autologous peripheral blood stem cell transplantation, ex vivo amplified
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Chronic Lymphocytic Leukemia
Ibrutinib Adapted to Response in Patients With CLL
As everyone knows in clinical practice, Ibrutinib dose reduction in patients with CLL with good response does not alter disease-free survival (DFS) or increase the risk of transformation.
- Trial name
- NCT05360758
- Testing
- Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia
- Volunteers
- 80 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Renal Cell Carcinoma
A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation
Renal cancer has traditionally been treated by surgical removal of the tumor, as the tumors are resistant to chemotherapy and radiation.
- Trial name
- NCT02075658
- Testing
- AirSeal® System-Interventional, Conventional Insufflator and Trocar
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-II
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-II (NCT03655821)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Radboud University Medical Center
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Leukemia, Leukemia, Myeloid
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib)…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome
- Trial name
- NCT01602952
- Testing
- Radotinib
- Where
- 12 sites in India, South Korea and 1 more
- Volunteers
- 85 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Meningioma
Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide
Meningiomas are the most common primary tumors of the central nervous system, representing more than a third of tumors.Current conventional treatments for meningioma are surgery and radiotherapy.
- Trial name
- MELUTE (NCT06255249)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This is a phase 2, single-centre, randomized, multi-cohort trial of subjects with advanced Mismatch Repair Proficient Colorectal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), and Leiomyosarcoma (LMS).
- Conditions
- Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
- Trial name
- DAPPER (NCT03851614)
- Testing
- Durvalumab, Olaparib, Cediranib
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Osteosarcoma
Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients
The purpose of this study is to develop indices predicting response to pre-operative chemotherapy in osteosarcoma patients. Histologic response to pre-operative chemotherapy is very important for the ultimate outcome of…
- Trial name
- NCT00686738
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- National Cancer Center, Korea
Vital Pulp Therapy
Effect of Topical Dexamethasone on Histologic Response of Human Dental Pulp
Abstract Aim The aim of this randomized clinical trial was to histologically investigate possible effects of dexamethasone application on pulp tissue healing during one step mineral trioxide aggregate (MTA)-direct pulp capping…
- Trial name
- NCT02574468
- Testing
- Dexamethasone applied on pulp or Dexamethasone did not applied on pulp, DPC or MP
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Adenocarcinoma, Pancreas, Neuroendocrine Carcinoma of Pancreas
Role of Perfusion CT in Pancreatic Cancer
The purpose of this study is 1. to determine whether the perfusion parameters in the normal pancreas and the pancreas cancer (adenocarcinoma or neuroendocrine tumor) are different on perfusion CT 2.
- Trial name
- NCT01703650
- Testing
- iopromide, CT
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.